Exercise decreases waist circumference in humans (T2DM-associated dyslipidemia).
“participants in the experimental group demonstrated statistically significant reductions across all obesity-related measures, including BMI (p < 0.0001), waist circumference (p < 0.0001), and WHR (p < 0.0001).”
Human trialT2DM-associated dyslipidemia12 weeksn = 57
medRxiv : the preprint server for health sciences·Preprint
Exercise decreases waist circumference in humans (MD -2.03 cm (95% CI -4.06 to -0.01, p = 0.05)).
“exercise (aerobic, resistance, or combined training) significantly reduced abdominal obesity, demonstrated by a decrease in waist circumference (WC) with a mean difference (MD) of -2.03 cm”
“Improvements in waist circumference, aerobic capacity, muscular strength, flexibility, and balance were observed postprogram in both male and female participants.”
Exercise improves waist circumference in humans (type 2 diabetes) (P<.001).
“On the completion of the 8-week program, significant improvements in waist circumference, aerobic capacity, muscular strength, flexibility, and balance were observed in both male and female participants (all P<.001).”
Human trialtype 2 diabetesweb-delivered, clinician-led group exercise and education program via videoconference8 weeksn = 171
Exercise showed no clear effect on waist circumference in humans (92.7 + 11.5 cm vs 92.3 + 11.7 cm).
“Moreover, the anthropometric assessment at T1, did not show any significant change in the mean values of WC, considered the main criterion of dysmetabolism, compared to those observed at baseline, in both the experimental and control group.”
Physical activity decreases waist circumference in humans (median difference −1, 95% CI −3 to 0).
“Between-group comparisons revealed significant differences in changes in waist (median difference [95%CI]: −1 [−3 to 0], p = 0.025) and hip (median difference [95%CI]: −1 [−2 to 0], p = 0.047) circumferences, with a greater reduction observed in the intervention group.”
Cholecalciferol decreases waist circumference in humans (from 12 to 24 weeks) (net difference: − 4.4 cm [95%CI − 8.1, − 0.8 cm], P = 0.017).
“Waist circumference and WHR decreased from 12 to 24 weeks, and stair climb time decreased from baseline to 12 weeks, in the vitamin D group compared with placebo.”
Tirzepatide decreases waist circumference in humans (SURMOUNT-1; across premenopause, perimenopause and postmenopause stages, versus placebo) (22 vs 4 cm (premenopause); 20 vs 5 cm (perimenopause); 20 vs 4 cm (postmenopause)).
“Greater waist circumference reductions were also observed with tirzepatide across the subgroups (22 vs. 4 cm, 20 vs. 5 cm, and 20 vs. 4 cm, respectively; p < 0.001).”
Human trialSURMOUNT-1; across premenopause, perimenopause and postmenopause stages, versus placebo15 mg or maximum tolerated dosefemales
Resistance training decreases waist circumference in humans (-4.1% [CI 95% -6.9 to -1.4]).
“WC (-4.1% [CI 95% -6.9 to -1.4]), WHtR (-4.2% [CI 95% -7.0 to -1.4]) and BRI (-10.3% [CI 95% -17.3 to -3.4]) improved in the HV when compared to the LV and CT.”
Human trialsix sets, 3 times/week, 70% 1RM16 weeksfemales
Resistance training decreases waist circumference in humans (postmenopausal women).
“In HV, a decrease in total cholesterol, LDL-c, WC, and WHR was noted.”
Human trialpostmenopausal womenhigh-volumesix sets/exercise; eight exercises at 70 % of one maximal repetition, three times a week16 weeksfemalesn = 11
Testosterone decreases waist circumference in humans (hypogonadal men with type 2 diabetes) (-1.63 +/- 0.71 cm, P = 0.03).
“Testosterone treatment resulted in a reduction in visceral adiposity as assessed by waist circumference (-1.63 +/- 0.71 cm, P = 0.03) and waist/hip ratio (-0.03 +/- 0.01, P = 0.01).”
Human trialhypogonadal men with type 2 diabetesi.m.200 mg every 2 weeks3 monthsmales
Ketogenic diet decreases waist circumference in humans (-4.08 cm (95% CI: -5.99 to -2.17)).
“Despite this, the KD led to significant reductions in abdominal circumference at both 6 weeks (−2.70 cm, 95% CI: −4.61 to −0.79, p = 0.006) and 12 weeks (−4.08 cm, 95% CI: −5.99 to −2.17, p < 0.001).”
Ketogenic diet decreases waist circumference in humans (polycystic ovary syndrome) (MD = -5.74 cm, 95% CrIs -8.48 to -3.04).
“the ketogenic diet reduced waist circumference (No (number of participants) = 86, k (number of study arms) = 2; MD = -5.74 cm, 95% CrIs -8.48 to -3.04)”
International journal of environmental research and public health·
Combined aerobic and resistance training decreases waist circumference in humans.
“Indeed, the 20–29y group decreased (p < 0.05) three (WC, p < 0.0001; SBP, p = 0.011; and FPG, p = 0.013), the 30–39y only one (WC, p < 0.0001), the 40–49y group three (WC, p < 0.0001; Tg, p = 0.014; and FPG, p = 0.048), and the 50–59 age group only one (WC, p = 0.002) MetS outcomes after CT.”
High-intensity interval training decreases waist circumference in humans (compared with moderate-intensity continuous training) (MD = -1.33 cm, 95% CI -2.40 to -0.26).
“waist circumference (MD = -1.33 cm, 95% CI -2.40 to -0.26, P = 0.023)”
Human trialcompared with moderate-intensity continuous trainingn = 745
Tai chi decreases waist circumference in humans (hypertension) (SMD = -0.50, 95% CI [-0.72, -0.28]).
“In terms of improving waist circumference and waist-to-hip ratio (WHR), Tai Chi had a significant effect (SMD = -0.50, 95% CI [-0.72, -0.28], SUCRA = 90.4”
CT-388 decreases waist circumference in humans (Obesity or overweight with ≥1 weight-related comorbidity; exploratory post hoc analysis) (Waist circumference: −1.5% placebo, −11.6% at 8 mg, −12.4% at 16 mg, and −14.3% at 24 mg).
“treatment with ENI was associated with dose-dependent reductions in both markers of CA (WC and ICO) and markers of VA (VAI and PAI-1) at W48”
Human trialObesity or overweight with ≥1 weight-related comorbidity; exploratory post hoc analysis8 mg, 16 mg, and 24 mg weekly48 weeksn = 467
Alzheimer's & dementia : the journal of the Alzheimer's Association·
Cardiovascular disease
→mediatesin humans2HR 1.027
2 studies
Waist circumference is linked with cardiovascular disease in humans (of associations with early menarche, early menopause, and short reproductive lifespan).
“Waist circumference was a significant mediator of early menarche, early menopause, and a short reproductive lifespan.”
Humansof associations with early menarche, early menopause, and short reproductive lifespan
Waist circumference is linked with cardiovascular disease in humans (Mediated proportion 10.2%; natural indirect effect HR 1.027).
“Among the components of MetS, unhealthy waist circumference showed the largest estimated mediated proportion (PM = 10.2%; NIE HR = 1.027).”
HumansMediation of the association between depression and cardiovascular disease by unhealthy waist circumferenceAverage follow-up of 15 yearsn = 353,610
Waist circumference was not clearly linked with mortality in humans after additional adjustment for fitness (P = .86).
“The association between waist circumference and mortality persisted after further adjustment for smoking, baseline health status, and BMI (P = .02) but not after additional adjustment for fitness (P = .86).”
Humansafter additional adjustment for fitnessn = 2,603
Waist circumference was not clearly linked with all-cause mortality prediction in humans (Chronic kidney disease; independent and incremental prognostic value).
“waist circumference provided neither independent nor incremental prognostic value.”
HumansChronic kidney disease; independent and incremental prognostic value
Waist circumference mediates major adverse cardiovascular events in humans (mediation analysis, 24 months after semaglutide vs placebo) (64.0% mediation (95% CI 27.5, 179.6); wide CI, estimates reported as unreliable in supplementary analyses).
“Point estimates for % mediation were largest for waist circumference (64.0% [95% confidence interval (CI) 27.5, 179.6]), hsCRP (42.1% [17.9, 110.5])”
Human trialmediation analysis, 24 months after semaglutide vs placebo24 months
Waist circumference is linked with thyroid cancer in humans (between psychological distress and thyroid cancer) (proportion of 11.80% (95% CI, 4.41-36.00%)).
“waist circumference had the strongest mediating effect by a proportion of 11.80% (95% CI, 4.41-36.00%; P < 0.001).”
Humansbetween psychological distress and thyroid cancermedian 12.59 yearsn = 420,187
Waist circumference is linked with higher sarcopenic obesity prevalence in humans (obesity defined by waist circumference rather than BMI, with Ishii score for sarcopenia) (14.1% versus 3.2%).
“SO prevalence was 3.2% (BMI method) versus 14.1% (WC method), with moderate agreement (Kappa = 0.572).”
Humansobesity defined by waist circumference rather than BMI, with Ishii score for sarcopenia
Acetate is linked with waist circumference in humans (mediates Planetary Health Diet association) (7.6/3.1%).
“Mediation analyses indicated that seven metabolites partly mediated diet-WC association in both men and women: short-chain fatty acid acetate (7.6/3.1%, respectively)”
physical inactivity and depressive symptoms are linked with higher waist circumference in humans (compared to active without depressive symptoms) (OR: 3.09; 95%CI: 2.88-3.30).
area-level socioeconomic status is linked with lower waist circumference in humans (-1.76 cm (95% CI: -2.68, -0.83)).
“one standard deviation higher score in the area-level SES indicator (less disadvantage) was associated with 1.76 cm (95% CI: -2.68, -0.83) lower waist circumference.”
Locomotive dysfunction is linked with higher waist circumference in humans (propensity score-matched cohort) (84.9 vs. 82.5 cm (P = 0.047)).
“waist circumference (84.9 vs. 82.5 cm) and systolic blood pressure (SBP) (145 vs. 140 mmHg) in the LD group were significantly higher than in the non-LD group (P = 0.047, P = 0.023).”
8-year follow-up from Tromsø 6 to Tromsø 7 is linked with higher waist circumference in humans (women +1.3 cm (95% CI 1.0 to 1.5); men +1.4 cm (95% CI 1.2 to 1.6)).
“and also waist circumference, by 1.3 cm (95% CI 1.0 to 1.5) in women and 1.4 cm (95% CI 1.2 to 1.6) in men.”
Waist circumference is associated with hypertension in humans (Per 10-cm greater waist circumference) (aPR 1.10 per 10 cm, 95% CI 1.02–1.20).
“Greater waist circumference (aPR 1.10 per 10 cm, 95% CI 1.02–1.20) and waist-to-height ratio (aPR 1.24 per 0.1 unit, 95% CI 1.13–1.37) were similarly associated with hypertension.”
Waist circumference predicts hypertension in humans (Discrimination among routinely available anthropometric measures) (AUC 0.791, 95% CI 0.780–0.802).
“Among routinely available anthropometric measures, waist circumference demonstrated the highest discriminatory performance for hypertension (AUC 0.791, 95% CI: 0.780-0.802).”
HumansDiscrimination among routinely available anthropometric measuresn = 7,817
Waist circumference is linked with a higher risk of hypertension in humans (OR 1.079, 95% CI 1.038–1.122).
“The odds of clinical hypertension increased independently by 1.079 times (OR=1.079; 95% CI=1.038–1.122) for every one-centimeter increase in waist measurement.”
International journal of environmental research and public health·
Waist circumference is linked with a higher risk of frailty in humans (OR 2.14, 95% CI 1.59 to 2.87).
“Participants with high (OR 2.14, 95% CI 1.59 to 2.87) or moderately high (OR 1.57, 95% CI 1.21 to 2.03) baseline WC were more likely to be pre-frail/frail than those with normal WC.”
Waist circumference is associated with frailty in humans (OR 1.20 (1.01-1.42)).
“Compared with T2 (77-85 cm) of WC, the OR (95%CI) of female T1 (<77 cm) and T3 (≥86 cm) group was 1.20 (1.01-1.42) and 1.10 (0.93-1.31), respectively.”
Waist circumference is associated with frailty in humans (aOR 4.18).
“Higher waist circumference, VAT, sarcopenia, and femoral neck osteoporosis were associated with increased odds of frailty (aOR 4.18, 4.45, 4.15, and 13.6, respectively, and all P < 0.05)”
Waist circumference predicts type 2 diabetes in humans.
“Abdominal adiposity indices (e.g., WC, waist-to-height ratio [WHtR], body roundness index [BRI]) outperformed general adiposity indices (e.g., BMI) in predicting T2DM risk.”
Waist circumference is linked with a higher risk of type 2 diabetes in humans (cross-sectional survey in Yangon, Myanmar) (AOR = 8.38, 95% CI: 2.30-30.54).
Waist circumference predicts type 2 diabetes in older women (AUC = 0.63, OR = 2.34).
“For women, however, the WC (AUC = 0.63; ES = 0.46; OR = 2.34) and C-Index (AUC = 0.63; ES = 0.46; OR = 2.34) were better indicators for predicting T2DM.”
Waist circumference is linked with a higher risk of type 2 diabetes in humans (compared with the first WC quintile, fully adjusted).
“Compared with the first WC quintile, the ORs and 95% CIs from the second to fifth quintiles for T2DM were 1.322 (1.244-1.404), 1.549 (1.459-1.643), 1.705 (1.609-1.807) and 2.169 (2.048-2.297)”
Humanscompared with the first WC quintile, fully adjustedn = 69,388
Waist circumference is associated with mortality in humans (WC at or above age- and BMI-specific median) (16% higher mortality per 5 cm; reported 95% CI 1.16 to 1.17).
“Each 5 cm increase in WC was associated with 16% (95% CI 1.16 to 1.17) and 14% (95% CI 1.14 to 1.15) higher mortality”
HumansWC at or above age- and BMI-specific medianEach 5 cm increaseMean follow-up of 13.9 yearsmalesn = 8,905,225
Waist circumference is associated with mortality in humans (Waist circumference decrease beyond the annualized −1.2% threshold; validation sample) (Validation HR 3.54, 95% CI 2.55–4.92; training HR 3.89, 95% CI 3.35–4.52).
“Decreases in BMI and WC were associated with increased risk”
HumansWaist circumference decrease beyond the annualized −1.2% threshold; validation sample
Waist circumference is linked with a lower risk of mortality in humans (HR 0.969, 95% CI 0.949-0.989).
“waist circumference and total cholesterol (P=0.003, HR=0.969, 95% CI=0.949-0.989 and P=0.046, HR=0.993, 95% CI=0.986-1.000, respectively) showed a decreased risk of mortality”
Waist circumference predicts diabetes mellitus in humans (AUC = 0.61, r = 0.1446).
“Waist circumference showed the highest correlation with diabetes (r = 0.1446) and the highest, though modest, discrimination (area under the curve = 0.61).”
Nutrition, metabolism, and cardiovascular diseases : NMCD·
Waist circumference is associated with diabetes mellitus in humans.
“metabolic risk factors-particularly WC and TG-appeared to play a more prominent role in the development of incident diabetes than lifestyle-related factors.”
Waist circumference is associated with diabetes mellitus in humans.
“The results of this study evidenced a higher strength of association between the report of arterial hypertension and diabetes mellitus with BMI, WC and WHtR in the Brazilian population of older adults”
Waist circumference is associated with diabetes mellitus in humans (Self-reported diabetes).
“factors independently and positively associated with diabetes: gender, self-reported health, history of hypertension/dyslipidemia, polypharmacy, and waist circumference.”
Waist circumference is linked with a higher risk of cardiovascular disease in humans (moderate-high stable vs low-stable trajectory) (HR 1.24 (95% CI, 1.05-1.46)).
“1.24 (95% CI, 1.05-1.46) for the moderate-high stable trajectory group”
Humansmoderate-high stable vs low-stable trajectory
Nutrition, metabolism, and cardiovascular diseases : NMCD·
Waist circumference is associated with cardiovascular disease in humans (moderate-stable vs low-stable trajectory) (HR 1.08 (95% CI, 0.94-1.24)).
“Compared with the low-stable trajectory group, the hazard ratios (HRs) for CVD were 1.08 (95% CI, 0.94-1.24) for the moderate-stable trajectory group”
Waist circumference is linked with a lower risk of cognitive impairment in humans (fully adjusted for confounding variables) (OR 0.93 (95%CI 0.88-0.98), P = .012).
“analyses showed significant negative associations of WC [OR 0.93 (95%CI 0.88-0.98), P = .012], HC [OR 0.92 (95%CI 0.87-0.97), P = .004]”
Humansfully adjusted for confounding variablesn = 10,579
Waist circumference is associated with bone mineral density in humans (Skeletal site- and gender-specific associations after adjustment for confounders).
“The cardiovascular risk factors of raised WC, FBG, TG and low HDL were significantly associated with increased BMD”
HumansSkeletal site- and gender-specific associations after adjustment for confoundersbonen = 331
The Journal of clinical endocrinology and metabolism·
Testosterone replacement therapy
↕mixedin humans1
1 study
Testosterone replacement therapy is associated with waist circumference in humans (baseline SHBG > 28.1 nmol/L and age > 63.1 years (subgroup 4) in men with T2DM and TD).
“in subgroup 4 but not subgroup 1, the therapy was significantly associated with ∆waist circumference, ∆HbA1c and ∆IIEF.”
Human trialbaseline SHBG > 28.1 nmol/L and age > 63.1 years (subgroup 4) in men with T2DM and TDmales
The index scored 0.547 for distinguishing people with diabetes from those without, versus 0.601 for body mass index; higher scores mean better performance.The index scored 0.547 for distinguishing people with diabetes from those without, versus 0.601 for body mass index; higher scores mean better performance.